Multiple risk factors were associated with denials and longer wait times for biologic treatment in moderate to severe asthma, ...

Across six asthma biologics, adherence differed by the therapy given and was often low or irregular based on three adherence measures, according to a presentation here.This cross-sectional cohort ...

A 12-month interim analysis of the AGILE Phase III extension study confirms the long-term safety and efficacy of twice-yearly ...

Reslizumab may also prove to be efficacious in patients with a similar asthma phenotype. Dual inhibition of IL-4 and IL-13 with dupilumab represents a very promising avenue for biologic-based ...

Discover a study that compared the effectiveness of P043 versus omalizumab in managing uncontrolled allergic asthma.

Learn the vital steps to take when someone experiences a severe asthma attack, from recognizing danger signs to administering ...

In the SWIFT and ANCHOR trials, depemokimab demonstrated statistically significant reductions in nasal polyp size, ...

The Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for depemokimab for asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps ...

Asthma inhalers are one type of allergic asthma medication that can help when symptoms begin. Find out which other types of ...

Not all asthma medications are appropriate for children. For example, most biologics are approved only for children over age 12. Viral wheeze is a lung infection with symptoms similar to a common ...

Physicians are advised to initiate treatment with both biologics in a healthcare setting under close observation. The most common adverse reactions varied by indication and age. For asthma in ...

Until relatively recently the development of novel asthma anti-inflammatory therapy based on targeting cytokines has proven to be, for the most part, disappointing. The majority of biologics have ...